• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>慢性疾病与转化医学：英文版 >Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
【24h】

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma

机译：程序性死亡配体-1 /程序性死亡-1抑制疗法和程序性死亡配体-1在尿路上皮膀胱癌中的表达

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 著录项
  • 相关主题
机译：After two decades of unchanged paradigms,the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1(PD-Ll)/programmed death-1(PD1)inhibition therapy.Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition therapy in both second-line and first-line settings.However,the percentage of patients who benefit from anti-PD-Ll/anti-PDl therapy is still low.Many questions have been raised in the development of biomarkerdriven approaches for disease classification and patient selection.In this perspective,we discuss PD-L1/PD1 expression in urothelial bladder carcinoma,review approved anti-PD-Ll/anti-PDl agents for bladder cancer treatment and current ongoing studies investigating combination treatment strategies,and explore PD-L1 expression status for the evaluation of bladder cancer immunotherapy.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号